• printer friendly
• mail this article
• iPod format
• digg

Photo

With increasing advancements in research into the human genome, a group of experts will meet at UCLA this weekend to discuss the benefits and problems arising from the interaction between genetic research and industry.

Speakers at the symposium, which is being hosted by the UCLA Center for Society and Genetics and titled “The Genetic Marketplace: A Citizen’s Guide to the Genomic Bazaar” include a former U.S. Surgeon General, a legal expert, professors and a genetic testing expert.

“We brought together a group of experts from around the country to begin to look at how we’re taking genomic materials and turning them into commodities,” said Edward McCabe, co-director of the UCLA Center for Society and Genetics and executive chair of the Department of Pediatrics at the UCLA David Geffen School of Medicine.

According to McCabe, genomic medicine will be predictive, preventive and personalized.

Patients’ genomes will be sequenced and this information will be used to determine which diseases they are prone to have, so lifestyle changes and medications can then be prescribed.

“Rather than treating everybody with the same medication and the same dose, we can look at genes to see if someone is susceptible to side effects or not so we can personalize the medicine to that individual,” McCabe said.

One of several topics that will be discussed is gene patenting.

For instance, some companies hold patents on a portion of the genes that make up the human genome, and as a result of those licensing fees, the cost of sequencing an individual’s genome is increased.

Additionally, Norton Wise, co-director of the UCLA Center for Society and Genetics, plans to discuss the politicization and commercialization of scientific research.

“I and many other people are concerned about university research and that it’s becoming bound up with commercialization,” Wise said.

“The commercialization may direct research into areas that are potentially profitable and not necessarily in the direction of public interest.”

New institutes of oversight protecting public interests are needed to resolve this issue as well as the politicization of research. The institutes should be the product of academic, industrial and governmental collaborations, Wise added.

To illustrate the importance of keeping commercialization out of research, Wise cited an example of an experimental result which asserted that people taking aspirin for conditions such as heart disease were developing a resistance to aspirin.

The study suggested that these people should take another drug, Plavix, instead.

The public was not told that this research project was funded by Plavix. Among the people who objected to the research findings, some were found to be funded by Bayer, a company which produces aspirin.

“Is there not any neutral source from which you can find trustworthy knowledge?” Wise said. “We need to have some way of judging when the results are the results that represent the public interest. There is an immense promise of development of research and technology that we need to preserve the public interest.”

Other speakers at the symposium will address topics such as the relationship between race and medicine as well as the positive interactions that can arise between corporations and genetics.

The issue of who owns a person’s genes will be discussed by Lori Andrews, a legal expert in genetic technologies.

“I decide who gets my money after I die. ... There’s something psychologically beneficial to me as a living person to know I can give my money to whoever I want,” Andrews said in a New York Times article in which she compares the right to decide how one’s tissues are used to the ability to determine where one’s money goes.

The UCLA Center for Society and Genetics was established in 2004. It is involved in research and education that is interdisciplinary. This is the fifth public symposium hosted by the center.